Any current/future new fundraising through debt or equity?

The company plans a capital expenditure (capex) of around INR 250-300 crores over the next 15 to 18 months for capacity expansion, including debottlenecking and new products. This capex will be funded through a mix of internal accruals and debt. The balance sheet is strong enough to support additional borrowing, and the immediate capex needs will be met through internal accruals and debt. Fundraising through Qualified Institutional Placement (QIP) or equity may be considered in the future based on requirements, but there is no immediate plan. The company will take a call on any potential fundr

Any current/future capex/capital investment/strategic investment?

Privi Specialty Chemicals plans a capex of INR 250-300 crores over the next 15-18 months for capacity expansion and debottlenecking of flagship products. This capex includes increasing existing product capacities and setting up capacities for a few new products. New products under development will form the next phase of expansion, for which Environmental Clearances (EC) and permissions have already been applied. The capex will be funded through a mix of internal accruals and debt. No immediate fundraising like QIP is planned; however, it may be considered in the future based on requirements. T

Future growth expectations in sales/revenue/volumes?

The company is very bullish about growth, aiming for a minimum of 20% revenue growth for FY 2025-26, with volume growth around 15%. A healthy order booking position of 65-70% for calendar year 2025 supports this confidence. Product mix improvements and internal efficiency enhancements contribute to margin sustainability and growth. Expansion through capacity increases and debottlenecking will support volume growth over the next 1-2 years. New product development, including high-value specialty products and new flagship products, will add to growth. Geographical expansion into markets

Future growth expectations in earnings/operating earnings/profits/EPS?

The company is confident of maintaining a minimum 20% revenue growth for FY 25-26, backed by a healthy order book of 65-70% already secured. Operating margins are expected to be sustained at around 20-23%, supported by improved yields, process efficiencies, and a favorable product mix. EBITDA margin for Q3 was around 23%, with expectations to maintain similar margins going forward. Profit after tax grew significantly, with Q3 PAT at INR 44 crores vs INR 29 crores last year; 9-month PAT increased 92% YoY to INR 121 crores. Volume growth expected to be around 15% corresponding to the rev

Current/ Expected Orderbook/ Pending Orders?

The company has a healthy order booking position with about 65% to 70% of orders already confirmed for calendar year 2025. Around 70% of the business is contracted, primarily with large multinational F&F and FMCG companies, following calendar-year contracts. The remaining 30% is mostly spot market sales and largely within the Indian market. Management is confident about achieving revenue growth guided for FY25 and maintaining strong margins due to secured raw materials aligned with production volumes. There is visibility and confidence for a good order book position for the next few quarters,

IN US

Sale is live|00:00:00left today

Privi Speciality Chemicals LtdQ4 FY26Chemicals & Petrochemicals

Privi Speciality Chemicals Ltd Q4 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹3,607P/E: 36.9Market Cap: ₹12.1K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

Yes

Order

Yes

Capex

Yes

3 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→The company is very bullish about growth, aiming for a minimum of 20% revenue growth for FY 2025-26, with volume growth around 15%.
→A healthy order booking position of 65-70% for calendar year 2025 supports this confidence.
→Product mix improvements and internal efficiency enhancements contribute to margin sustainability and growth.
→Expansion through capacity increases and debottlenecking will support volume growth over the next 1-2 years.
→New product development, including high-value specialty products and new flagship products, will add to growth.
→Geographical expansion into markets like India, Africa, South Asia, and China is expected to drive growth, with >20% growth anticipated from Indian and African markets.
→The Givaudan JV is ramping up and on track, supporting future revenue increases.
→Ongoing R&D and planned capacity expansions worth INR 250-300 crores over 15-18 months will facilitate this growth.

Margin guidance

Category 3

→The company is confident of maintaining a minimum 20% revenue growth for FY 25-26, backed by a healthy order book of 65-70% already secured.
→Operating margins are expected to be sustained at around 20-23%, supported by improved yields, process efficiencies, and a favorable product mix.
→EBITDA margin for Q3 was around 23%, with expectations to maintain similar margins going forward.
→Profit after tax grew significantly, with Q3 PAT at INR 44 crores vs INR 29 crores last year; 9-month PAT increased 92% YoY to INR 121 crores.
→Volume growth expected to be around 15% corresponding to the revenue growth of ~20%.
→Continuous capacity expansions, debottlenecking, and new products (including JV with Givaudan) to support future earnings growth.
→New product launches and entry into new geographies like Africa and India are expected to contribute positively.
→The company aims to capitalize on all opportunities dynamically to sustain growth and margins.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→The company plans a capital expenditure (capex) of around INR 250-300 crores over the next 15 to 18 months for capacity expansion, including debottlenecking and new products.
→This capex will be funded through a mix of internal accruals and debt.
→The balance sheet is strong enough to support additional borrowing, and the immediate capex needs will be met through internal accruals and debt.
→Fundraising through Qualified Institutional Placement (QIP) or equity may be considered in the future based on requirements, but there is no immediate plan.
→The company will take a call on any potential fundraises at an opportune time, depending on the demand and market environment.

Order book

Yes

→The company has a healthy order booking position with about 65% to 70% of orders already confirmed for calendar year 2025.
→Around 70% of the business is contracted, primarily with large multinational F&F and FMCG companies, following calendar-year contracts.
→The remaining 30% is mostly spot market sales and largely within the Indian market.
→Management is confident about achieving revenue growth guided for FY25 and maintaining strong margins due to secured raw materials aligned with production volumes.
→There is visibility and confidence for a good order book position for the next few quarters, supporting growth.
→The company expects no major disruptions in the order book despite geopolitical uncertainties.
→The current capacity expansion and debottlenecking exercises support volume growth for the next 1-2 years, aligning with the current order book.

Capex plans

Yes

→Privi Specialty Chemicals plans a capex of INR 250-300 crores over the next 15-18 months for capacity expansion and debottlenecking of flagship products.
→This capex includes increasing existing product capacities and setting up capacities for a few new products.
→New products under development will form the next phase of expansion, for which Environmental Clearances (EC) and permissions have already been applied.
→The capex will be funded through a mix of internal accruals and debt.
→No immediate fundraising like QIP is planned; however, it may be considered in the future based on requirements.
→The company is also exploring co-manufacturing arrangements with competitors, though details are confidential.
→Continuous process development and greenfield projects (e.g., JV with Givaudan) are part of growth strategy.
→Capacity enhancements and new product launches aim to support 20%+ revenue growth in coming years.

How does Privi Speciality Chemicals Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Privi Speciality Chemicals Ltd

Rev 2Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Privi Speciality Chemicals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio